Phase I, first-in-man, randomised, placebo-controlled, single dose escalation study to investigate the effects of LPH-5 on safety, tolerability, pharmacokinetic and pharmacodynamic parameters in healthy participants

What you commit to

• Study type: Interventional · Phase 1
• Participants enrolled: 56
• 1 site in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

Are you the coordinator? Confirm the details